{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:07:10Z","timestamp":1767006430828,"version":"3.37.3"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T00:00:00Z","timestamp":1393200000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089015","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T21:47:48Z","timestamp":1393278468000},"page":"e89015","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["rtM204Q May Serve as a Novel Lamivudine-Resistance-Associated Mutation of Hepatitis B Virus"],"prefix":"10.1371","volume":"9","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojie","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,24]]},"reference":[{"key":"ref1","unstructured":"World Health Organization (2012) Hepatitis B fact sheets. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/<\/ext-link>. Updated on July, 2013. Accessed on January 1, 2013."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcr270","article-title":"Hepatitis B infection: current concepts and future challenges","volume":"105","author":"G Nebbia","year":"2012","journal-title":"QJM"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/liv.12065","article-title":"Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue","volume":"33","author":"H Ma","year":"2013","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic Hepatitis B: Update 2009","volume":"50","author":"AS Lok","year":"2009","journal-title":"Hepatology"},{"key":"ref5","first-page":"777","article-title":"Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther","volume":"7","author":"DC Chao","year":"2013"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Soriano V, McMahon B (2013) Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Res. doi:10.1016\/j.antiviral.2013.08.026<\/ext-link>.","DOI":"10.1016\/j.antiviral.2013.08.026"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zoulim F, Locarnini S (2013) Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int Suppl 1: 116\u2013124. doi:10.1111\/liv.12069<\/ext-link>.","DOI":"10.1111\/liv.12069"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2005.11.036","article-title":"Cellular and virological mechanisms of HBV drug resistance","volume":"44","author":"S Locarnini","year":"2006","journal-title":"J Hepatol"},{"key":"ref9","first-page":"687","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis","volume":"36","author":"CL Lai","year":"2003"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2008.12.005","article-title":"Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture","volume":"50","author":"LK Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"ref11","first-page":"247","article-title":"Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut","volume":"60","author":"SJ Patterson","year":"2011"},{"key":"ref12","first-page":"324","article-title":"Management scheme of diagnostic and therapy criteria of viral hepatitis","volume":"8","year":"2000","journal-title":"Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol)"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Xu D, Fu J, Jin L, Zhang H, Zhou C, et al. (2006) Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177: 739\u2013747. PMID: 16785573.","DOI":"10.4049\/jimmunol.177.1.739"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1365-2893.2010.01360.x","article-title":"Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection","volume":"18","author":"Y Liu","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e72799","DOI":"10.1371\/journal.pone.0072799","article-title":"Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population","volume":"8","author":"Z Xu","year":"2013","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939759","article-title":"In vitro models for studying hepatitis B virus drug resistance","volume":"26","author":"F Zoulim","year":"2006","journal-title":"Semin Liver Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2012.02.003","article-title":"The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation","volume":"54","author":"D Ji","year":"2012","journal-title":"J Clin Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","article-title":"Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks","volume":"36","author":"H Yang","year":"2002","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"AS Lok","year":"2007","journal-title":"Hepatology"},{"key":"ref20","first-page":"2576","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med","volume":"357","author":"CL Lai","year":"2007"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1365-2893.2003.00435.x","article-title":"YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine","volume":"10","author":"AM Bozdayi","year":"2003","journal-title":"J Viral Hepat"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/JVI.74.14.6262-6268.2000","article-title":"Evolution of lamivudine resistance in human immunodeficiency virus type 1 infected individuals the relative roles of drift and selection","volume":"74","author":"S Frost","year":"2000","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"10027","DOI":"10.1073\/pnas.96.18.10027","article-title":"Lamivudine (3TC) resistance in HIV reverse transcriptase involves steric hindrance with beta-branched amino acids","volume":"96","author":"SG Sarafianos","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1006\/jmbi.2000.3823","article-title":"The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase","volume":"300","author":"HQ Gao","year":"2000","journal-title":"J Mol Biol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/hep.510290340","article-title":"YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection","volume":"29","author":"SK Ono-Nita","year":"1999","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1743-422X-7-167","article-title":"Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case","volume":"7","author":"V Schildgen","year":"2010","journal-title":"Virol J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3851\/IMP2307","article-title":"Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy","volume":"17","author":"F van B\u00f6mmel","year":"2012","journal-title":"Antivir Ther"},{"key":"ref28","first-page":"446","article-title":"Phenotypic characteristics of a novel mutation rtM204Q in the reverse-transcriptase domain of hepatitis B virus isolated from a chronic hepatitis B patient receiving lamivudine treatment","volume":"37","author":"Y Wang","year":"2012","journal-title":"Med J Chin PLA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/hep.22900","article-title":"Antiviral resistance and hepatitis B therapy","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virusres.2007.02.021","article-title":"Hepatitis B virus genetic variability and evolution","volume":"127","author":"A Kay","year":"2007","journal-title":"Virus Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3851\/IMP1495","article-title":"Drug-resistant and immune-escape HBV mutants in HIV-infected hosts","volume":"15","author":"K Lacombe","year":"2010","journal-title":"Antivir Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e37874","DOI":"10.1371\/journal.pone.0037874","article-title":"Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome","volume":"7","author":"F Rodriguez-Fr\u00edas","year":"2012","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/ncomms1794","article-title":"Convergence and coevolution of hepatitis B virus drug resistance","volume":"3","author":"H Thai","year":"2012","journal-title":"Nat Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1128\/AAC.00239-06","article-title":"Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif","volume":"50","author":"H Yatsuji","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/JCM.02477-05","article-title":"Detection of rtN236T and rtA181V\/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2)","volume":"44","author":"C Osiowy","year":"2006","journal-title":"J Clin Microbiol"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, et al. (2006) Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 11: 1103\u20131106. PMID: 17302381.","DOI":"10.1177\/135965350601100801"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T18:44:34Z","timestamp":1689014674000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089015"}},"subtitle":[],"editor":[{"given":"Jean-Pierre","family":"Vartanian","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,24]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089015","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2014,2,24]]}}}